Optimal anticoagulation in elderly patients with atrial fibrillation: Which drug at which dose?

Jo Nan Liao; Yi Hsin Chan; Ling Kuo; Chuan Tsai Tsai; Su Shen Lim; Tze Fan Chao

doi:10.33963/KP.a2022.0046

Optimal anticoagulation in elderly patients with atrial fibrillation: Which drug at which dose?

Jo Nan Liao, Yi Hsin Chan, Ling Kuo, Chuan Tsai Tsai, Su Shen Lim, Tze Fan Chao^*

^*Corresponding author for this work

School of Traditional Chinese Medicine

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Aging is an important risk factor for adverse events in elderly patients with atrial fibrillation (AF) and complicates the management of anticoagulation. Underuse of oral anticoagulants (OACs) is common in elderly patients because of comorbidities, the altered physiological function of multiple organs, frailty, risk of falls, and the lack of randomized controlled trials (RCTs) specifically for elderly patients. Nevertheless, current data still support OACs use for reducing ischemic stroke with positive net clinical benefits. Sub-analyses of RCTs and real-world cohort studies showed that non-vitamin K antagonist OACs (NOACs) would be more favorable choices compared to warfarin for stroke prevention in the elderly. This review will discuss important data on stroke prevention and the use of NOACs in elderly AF patients.

Original language	English
Pages (from-to)	128-136
Number of pages	9
Journal	Kardiologia Polska
Volume	80
Issue number	2
DOIs	https://doi.org/10.33963/KP.a2022.0046
State	Published - 2022

Bibliographical note

Publisher Copyright:
© by the Polish Cardiac Society, 2022.

Keywords

NOAC
anticoagulation
atrial fibrillation
elderly
stroke

Access to Document

10.33963/KP.a2022.0046

Cite this

@article{55d037bea70143d8895b93877f1b82e5,

title = "Optimal anticoagulation in elderly patients with atrial fibrillation: Which drug at which dose?",

abstract = "Aging is an important risk factor for adverse events in elderly patients with atrial fibrillation (AF) and complicates the management of anticoagulation. Underuse of oral anticoagulants (OACs) is common in elderly patients because of comorbidities, the altered physiological function of multiple organs, frailty, risk of falls, and the lack of randomized controlled trials (RCTs) specifically for elderly patients. Nevertheless, current data still support OACs use for reducing ischemic stroke with positive net clinical benefits. Sub-analyses of RCTs and real-world cohort studies showed that non-vitamin K antagonist OACs (NOACs) would be more favorable choices compared to warfarin for stroke prevention in the elderly. This review will discuss important data on stroke prevention and the use of NOACs in elderly AF patients.",

keywords = "NOAC, anticoagulation, atrial fibrillation, elderly, stroke",

author = "Liao, {Jo Nan} and Chan, {Yi Hsin} and Ling Kuo and Tsai, {Chuan Tsai} and Lim, {Su Shen} and Chao, {Tze Fan}",

note = "Publisher Copyright: {\textcopyright} by the Polish Cardiac Society, 2022.",

year = "2022",

doi = "10.33963/KP.a2022.0046",

language = "英语",

volume = "80",

pages = "128--136",

journal = "Kardiologia Polska",

issn = "0022-9032",

publisher = "Via Medica",

number = "2",

}

TY - JOUR

T1 - Optimal anticoagulation in elderly patients with atrial fibrillation

T2 - Which drug at which dose?

AU - Liao, Jo Nan

AU - Chan, Yi Hsin

AU - Kuo, Ling

AU - Tsai, Chuan Tsai

AU - Lim, Su Shen

AU - Chao, Tze Fan

N1 - Publisher Copyright: © by the Polish Cardiac Society, 2022.

PY - 2022

Y1 - 2022

N2 - Aging is an important risk factor for adverse events in elderly patients with atrial fibrillation (AF) and complicates the management of anticoagulation. Underuse of oral anticoagulants (OACs) is common in elderly patients because of comorbidities, the altered physiological function of multiple organs, frailty, risk of falls, and the lack of randomized controlled trials (RCTs) specifically for elderly patients. Nevertheless, current data still support OACs use for reducing ischemic stroke with positive net clinical benefits. Sub-analyses of RCTs and real-world cohort studies showed that non-vitamin K antagonist OACs (NOACs) would be more favorable choices compared to warfarin for stroke prevention in the elderly. This review will discuss important data on stroke prevention and the use of NOACs in elderly AF patients.

AB - Aging is an important risk factor for adverse events in elderly patients with atrial fibrillation (AF) and complicates the management of anticoagulation. Underuse of oral anticoagulants (OACs) is common in elderly patients because of comorbidities, the altered physiological function of multiple organs, frailty, risk of falls, and the lack of randomized controlled trials (RCTs) specifically for elderly patients. Nevertheless, current data still support OACs use for reducing ischemic stroke with positive net clinical benefits. Sub-analyses of RCTs and real-world cohort studies showed that non-vitamin K antagonist OACs (NOACs) would be more favorable choices compared to warfarin for stroke prevention in the elderly. This review will discuss important data on stroke prevention and the use of NOACs in elderly AF patients.

KW - NOAC

KW - anticoagulation

KW - atrial fibrillation

KW - elderly

KW - stroke

UR - http://www.scopus.com/inward/record.url?scp=85125681298&partnerID=8YFLogxK

U2 - 10.33963/KP.a2022.0046

DO - 10.33963/KP.a2022.0046

M3 - 文献综述

C2 - 35167115

AN - SCOPUS:85125681298

SN - 0022-9032

VL - 80

SP - 128

EP - 136

JO - Kardiologia Polska

JF - Kardiologia Polska

IS - 2

ER -

Optimal anticoagulation in elderly patients with atrial fibrillation: Which drug at which dose?

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this